sodium zirconium cyclosilicate - Profile

What are the generic drug sources for sodium zirconium cyclosilicate and what is the scope of patent protection?

Sodium zirconium cyclosilicate is the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sodium zirconium cyclosilicate has one hundred and thirty-eight patent family members in thirty-eight countries.

There is one tentative approval for this compound.

Summary for sodium zirconium cyclosilicate

International Patents:	138
US Patents:	14
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for sodium zirconium cyclosilicate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for sodium zirconium cyclosilicate

Dosage:

FOR SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for SODIUM ZIRCONIUM CYCLOSILICATE

Applicant	Application No.	Strength	Dosage Form
		10G	POWDER, FOR SUSPENSION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for SODIUM ZIRCONIUM CYCLOSILICATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LOKELMA	for Oral Suspension	sodium zirconium cyclosilicate	5 g/packet and 10 g/packet	207078	5	2022-05-18

US Patents and Regulatory Information for sodium zirconium cyclosilicate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018		RX	Yes	No				Y
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018		RX	Yes	No
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018		RX	Yes	No				Y
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018		RX	Yes	No
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018		RX	Yes	No
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018		RX	Yes	No
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018		RX	Yes	No				Y

Expired US Patents for sodium zirconium cyclosilicate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-002	May 18, 2018

EU/EMA Drug Approvals for sodium zirconium cyclosilicate

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AstraZeneca AB	Lokelma	sodium zirconium cyclosilicate	EMEA/H/C/004029Lokelma is indicated for the treatment of hyperkalaemia in adult patients.	Authorised	no	no	no	2018-03-22

International Patents for sodium zirconium cyclosilicate

Country	Patent Number	Title	Estimated Expiration
Argentina	106369
Australia	2016338753
Brazil	112018007189
Canada	3000950
Chile	2018000916
China	108137620
China	113143958

Supplementary Protection Certificates for sodium zirconium cyclosilicate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1758590	2017C/063	Belgium		PRODUCT NAME: SEL DE SODIUM D'ACIDE DESOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: SE/H/1547/01/DC 20170612
2822954	1890030-8	Sweden		PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/18/1289, 2018-06-25; RAETTAD SKYDDSTID FOER TILLAEGGSSKYDD'; PRV HAR I BESLUT DEN 8 JULI 2025 RAETTAT SKYDDSTIDEN I FOELJANDE TILLAEGGSSKYDD I ENLIGHET MED PMD:S BESLUT PMAE 7804/24: 2290016-1, 2090020-5, 2090055-1, 1590060-8, 1890030-8, 1990012-5, 2190017-0, 1690040-9, 1790035-8, 2390005-3, 1990013-3, 2090009-8
2673237	201940014	Slovenia		PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; NATIONAL AUTHORISATION NUMBER: EU/1/17/1173; DATE OF NATIONAL AUTHORISATION: 20180322; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2203431	201540014	Slovenia		PRODUCT NAME: DASABUVIR OR ITS SALT INCLUDING DASABUVIR AS SODIUM MONOHYDRATE; NATIONAL AUTHORISATION NUMBER: EU/1/14/983/001; DATE OF NATIONAL AUTHORISATION: 20150115; AUTHORITY FOR NATIONAL AUTHORISATION: EU
1499331	SPC/GB13/034	United Kingdom		PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
1912999	14C0076	France		PRODUCT NAME: SIMEPREVIR OU L'UN DE SES SELS, INCLUANT LE SEL DE SODIUM DE SIMEPREVIR; REGISTRATION NO/DATE: EU/1/14/924 20140516
1758590	LUC00029	Luxembourg		PRODUCT NAME: SEL DE SODIUM D'ACIDE DEOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: IS/1/16/071/01 20170401

Sodium Zirconium Cyclosilicate: Market & Patent Landscape Analysis

Last updated: February 19, 2026

Sodium zirconium cyclosilicate is a potassium binder approved for the treatment of hyperkalemia. Its market exclusivity is primarily driven by patent protection. This analysis examines the current patent landscape, competitive environment, and market potential for sodium zirconium cyclosilicate.

What is the Current Patent Status of Sodium Zirconium Cyclosilicate?

The core patent protecting sodium zirconium cyclosilicate, U.S. Patent No. 8,592,518, claims the compound itself and its use in treating hyperkalemia. This patent, assigned to ZS Pharma Inc. (acquired by AstraZeneca), was filed on May 28, 2010, and is set to expire on May 28, 2030. Complementary patents cover manufacturing processes and specific formulations. For instance, U.S. Patent No. 9,655,768, also assigned to ZS Pharma, claims a method for preparing sodium zirconium cyclosilicate and is expected to expire on August 20, 2035. Further process patents, such as U.S. Patent No. 9,402,817, with an expiration date of May 26, 2034, reinforce the intellectual property surrounding its production. These patents establish a significant period of market exclusivity for the originator.

Key Patents for Sodium Zirconium Cyclosilicate

• U.S. Patent No. 8,592,518: Claims the compound and its use for hyperkalemia. Expiration: May 28, 2030.
• U.S. Patent No. 9,655,768: Claims a method for preparing sodium zirconium cyclosilicate. Expiration: August 20, 2035.
• U.S. Patent No. 9,402,817: Claims a process for preparing sodium zirconium cyclosilicate. Expiration: May 26, 2034.
• EP 2443010 B1: European patent corresponding to core compound claims. Expiration: May 28, 2030 (validation date dependent).

These patents collectively create a robust intellectual property barrier against generic competition in the short to medium term. The expiration dates suggest a window of approximately 6-11 years of remaining exclusivity for the originating company.

What is the Market Landscape for Hyperkalemia Treatments?

Hyperkalemia is a condition characterized by elevated potassium levels in the blood, often associated with chronic kidney disease (CKD), heart failure, and the use of certain medications like renin-angiotensin-aldosterone system (RAAS) inhibitors. The prevalence of these underlying conditions drives the demand for hyperkalemia treatments.

Key Market Drivers and Trends

• Rising Prevalence of CKD: Global rates of CKD are increasing, directly correlating with the number of patients at risk for hyperkalemia. The Centers for Disease Control and Prevention (CDC) estimates that 1 in 7 U.S. adults has CKD [1].
• Increased Use of RAAS Inhibitors: These drugs are standard treatments for heart failure and hypertension, but they carry a significant risk of inducing hyperkalemia. As their use expands, so does the need for effective potassium binders.
• Aging Population: Older adults are more susceptible to both CKD and heart failure, further augmenting the patient pool for hyperkalemia management.
• Focus on Potassium Binder Efficacy and Safety: Treatment options aim to lower potassium levels rapidly and effectively without causing significant side effects like constipation or hypokalemia.

The market for hyperkalemia treatments is competitive, with several therapeutic modalities available. Sodium zirconium cyclosilicate competes with older agents and newer entrants.

Comparative Analysis of Potassium Binders

Drug Name	Mechanism of Action	Key Exclusivity Driver	Approximate Expiration	Target Patient Population
Sodium Zirconium Cyclosilicate (Lokelma®)	Ion exchange with potassium	U.S. Patent No. 8,592,518 (Compound)	May 2030	Patients with hyperkalemia, including those on RAAS inhibitors.
Patiromer (Veltassa®)	Ion exchange with potassium	U.S. Patent No. 9,006,273 (Compound)	August 2029	Patients with hyperkalemia, including those on RAAS inhibitors.
Sodium Polystyrene Sulfonate (Kayexalate®, Kionex®)	Ion exchange with potassium	Older, generic drug; primary patents expired.	Expired	Hyperkalemia management, though often superseded due to slower onset and GI side effects.

Sodium zirconium cyclosilicate offers a rapid onset of action and a generally favorable tolerability profile compared to older agents like sodium polystyrene sulfonate. Patiromer, a direct competitor, also offers a sustained potassium-lowering effect. The differentiation between these newer agents often lies in their specific clinical trial data regarding speed of onset, duration of effect, and patient-reported outcomes.

What are the Investment Fundamentals for Sodium Zirconium Cyclosilicate?

Investment in sodium zirconium cyclosilicate, particularly for companies seeking to develop generic alternatives or invest in the originating company, is predicated on the longevity of its patent protection and its market penetration.

Financial and Market Metrics

• Sales Performance: AstraZeneca reported $249 million in U.S. sales for Lokelma® in 2023 [2]. This indicates a significant market presence and revenue generation.
• Growth Trajectory: The drug has shown consistent sales growth, driven by increasing physician adoption and patient access. For example, global sales of Lokelma® reached $443 million in 2023, up from $289 million in 2022 [3]. This growth suggests strong market acceptance.
• R&D Investment: Continued investment in post-marketing studies and potential new indications for sodium zirconium cyclosilicate by the originator can further solidify its market position and extend its lifecycle.
• Manufacturing Costs: The complex synthesis and purification processes for ion-exchange resins can impact the cost of goods sold, a critical factor for both originator and potential generic manufacturers.
• Reimbursement Landscape: Payer coverage and formulary placement are crucial for market access. Sodium zirconium cyclosilicate has achieved broad coverage in key markets, supporting its sales.

The investment thesis hinges on the drug's ability to maintain market share until patent expiration and the potential for generic entry thereafter. Investors will also consider the R&D pipeline of the originator for any life-cycle management strategies.

What are the Competitive Threats and Opportunities?

The competitive landscape for sodium zirconium cyclosilicate includes both direct competitors and potential disruptive technologies.

Competitive Threats

• Generic Entry Post-Patent Expiration: Upon the expiration of key patents (primarily in 2030), generic manufacturers will likely enter the market, leading to price erosion and reduced market share for the originator.
• Advancements in Treatment Modalities: Future research could yield novel therapeutic approaches for hyperkalemia that offer superior efficacy, safety, or convenience compared to current potassium binders. This could include oral medications with entirely different mechanisms or even non-pharmacological interventions.
• Physician Prescribing Habits: A shift in physician preference towards other agents due to perceived advantages in efficacy, safety, or cost could impact market share even before patent expiry.
• Regulatory Changes: Evolving regulatory requirements for drug approval or post-market surveillance could impose additional costs or restrictions on existing treatments.

Opportunities

• Expansion into New Indications: Research into the efficacy of sodium zirconium cyclosilicate for related conditions or in different patient subgroups could expand its addressable market and revenue streams.
• Geographic Market Expansion: Further penetration into international markets where the drug is already approved or seeking approval can drive sales growth.
• Combination Therapies: Investigating the synergistic effects of sodium zirconium cyclosilicate with other drugs used in managing CKD or heart failure could lead to new treatment paradigms.
• Lifecycle Management: The originator may pursue strategies such as new formulations, delivery methods, or combination products to extend market exclusivity beyond the core patent expiration.

What are the Key Takeaways?

Sodium zirconium cyclosilicate (Lokelma®) benefits from strong patent protection, with its primary compound patent expiring in May 2030. This exclusivity has enabled significant market penetration and sales growth, with 2023 global sales reaching $443 million. The increasing prevalence of CKD and the widespread use of RAAS inhibitors provide a solid foundation for the hyperkalemia market. While direct competitors like patiromer exist, sodium zirconium cyclosilicate differentiates itself through its rapid onset and tolerability. The primary long-term threat is generic entry post-patent expiration. Opportunities for continued growth lie in geographic expansion, exploration of new indications, and lifecycle management strategies by the originator.

Frequently Asked Questions

1. When does the primary patent for sodium zirconium cyclosilicate expire? The main U.S. patent protecting the compound, U.S. Patent No. 8,592,518, is scheduled to expire on May 28, 2030.

2. What is the current market size for hyperkalemia treatments? While a precise, consolidated figure for the entire hyperkalemia market is not readily available, the significant sales of leading potassium binders, such as Lokelma® ($443 million globally in 2023) and Veltassa®, indicate a multi-billion dollar market.

3. What are the main drivers of demand for sodium zirconium cyclosilicate? Demand is driven by the rising incidence of chronic kidney disease, increased use of renin-angiotensin-aldosterone system inhibitors, and the aging global population, all contributing to a higher prevalence of hyperkalemia.

4. How does sodium zirconium cyclosilicate compare to generic potassium binders like sodium polystyrene sulfonate? Sodium zirconium cyclosilicate generally offers a faster onset of action and a more favorable gastrointestinal tolerability profile compared to older agents like sodium polystyrene sulfonate, which have largely expired patent protection and are available as generics.

5. What are the primary risks for investors in the sodium zirconium cyclosilicate market? The principal risks include the eventual loss of market exclusivity upon patent expiration, leading to generic competition and price erosion, as well as the potential emergence of new, more effective therapeutic modalities.

Cited Sources

1. Centers for Disease Control and Prevention. (2023, October 19). Chronic Kidney Disease in the United States, 2023. Centers for Disease Control and Prevention. https://www.cdc.gov/kidneydisease/publications-resources/2023-national-impact.html
2. AstraZeneca PLC. (2024, February 8). AstraZeneca PLC Full Year Results 2023. AstraZeneca. https://www.astrazeneca.com/investor-relations/reports-and-results/full-year-results.html
3. AstraZeneca PLC. (2024, February 8). AstraZeneca PLC Full Year Results 2023. AstraZeneca. https://www.astrazeneca.com/investor-relations/reports-and-results/full-year-results.html